

13th November, 2025

To,
The Manager - Corporate Relationship Dept.
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001

To,
The Manager - Corporate Compliance
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1,
G Block, BKC, Bandra (E),
Mumbai 400 051

Scrip Code: BSE - 524500

Scrip Code: NSE - KILITCH

Sub: Outcome of Board Meeting

Dear Sir,

In continuation of our letter dated 8th November, 2025 and pursuant to Regulation 30 and Regulation 33 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby would like to inform you that the Board of Directors of the Company at its meeting held today i.e. Thursday, 13th November, 2025 have considered and approved the following;

1. Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th September, 2025. The copy of Unaudited Financial Results (Standalone and Consolidated) as considered and approved by the Board of Directors along with Limited Review Report by the Auditors are enclosed herewith for your ready reference.

The Board Meeting commenced at 16:45 hours and concluded at ~~18:40~~ 18:40 hours.

Request you to kindly take note of the same and acknowledge the receipt.

Thanking you,

Yours Faithfully,

For Kilitch Drugs (India) Limited

Mukund Mehta
Managing Director



Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of Kilitch Drugs (India) Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)


To,
The Board of Directors of
Kilitch Drugs (India) Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Kilitch Drugs (India) Limited** (the 'Company') for the quarter and half year ended 30th September, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended (the "Listing Regulations").
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition & measurement principles laid down in the Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules thereafter and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For C Sharat & Associate
Chartered Accountants
FRN: 128593W

CHINTAN
SHARATCHA
NDRA SHAH

Digitally signed by
CHINTAN
SHARATCHANDRA SHAH
Date: 2025.11.13 15:16:18
+05'30'



Chintan Sharatchandra Shah
Partner
Mem.No: 127551
UDIN: 25127551BMIIWG4924
Date: 13/11/2025
Place: Mumbai

KILITCH DRUGS (INDIA) LIMITED
STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30TH SEPTEMBER, 2025

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

CIN:L24239MH1992PLC066718

(Rs. In Lakhs except Earnings per Share data)

		Three Months Ended			Six Months Ended		Year Ended
		30-09-2025	30-06-2025	30-09-2024	30-09-2025	30-09-2024	31-03-2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	Net Sales/ Income from operations	3,781.35	3,412.20	4,534.84	7,193.55	7,877.00	18,158.73
	Other Income	760.89	349.52	580.90	1,110.41	902.06	1,371.53
	Total Income	4,542.24	3,761.72	5,115.74	8,303.96	8,779.06	19,530.26
2	Expenses						
	Cost of Materials Consumed	1,568.37	1,753.44	2,294.85	3,321.80	4,156.73	9,319.06
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	206.90	(76.09)	16.54	130.81	5.55	(116.99)
	Employee Benefit Expenses	328.25	239.50	249.32	567.74	471.77	1,003.07
	Finance Cost	67.86	58.66	42.04	126.52	91.04	212.55
	Depreciation and Amortisation Expenses	52.70	49.87	40.24	102.57	75.16	173.72
	Export Product Registration/Commission	527.11	550.50	560.90	1,077.61	934.69	1,994.23
	Other Expenses	783.66	587.67	853.81	1,371.33	1,426.93	2,875.63
	Total Expenses	3,534.85	3,163.55	4,057.70	6,698.38	7,161.87	15,461.27
3	Profit / (Loss) before Exceptional items (1-2)	1,007.39	598.17	1,058.04	1,605.58	1,617.19	4,068.99
4	Exceptional Items	-	-	-	-	-	-
5	Profit / (Loss) from ordinary activities before tax (3+4)	1,007.39	598.17	1,058.04	1,605.58	1,617.19	4,068.99
6	Less: Tax Expenses:-						
	Current Tax	178.14	129.86	216.09	308.00	342.59	985.00
	Deferred Tax	(42.32)	(11.10)	(42.64)	(53.43)	(15.37)	(31.70)
7	Net Profit / (Loss) after Tax for the period from Continuing Operations (5-6)	871.57	479.41	884.59	1,351.01	1,289.97	3,115.69
8	Other Comprehensive Income (after tax)	(229.86)	293.49	(13.19)	63.64	102.83	(113.68)
9	Total Comprehensive Income (after taxes) (7+8)	641.71	772.90	871.40	1,414.65	1,392.80	3,002.01
10	Paid-Up equity share capital (Face Value Rs 10 per share)	1,748.08	1,608.23	1,608.23	1,748.08	1,608.23	1,608.23
11	Other Equity	-	-	-	-	-	23,686.14
12	Earning per share (not annualised)						
	(a) Basic	5.27	2.98	5.50	8.26	8.02	19.37
	(b) Diluted	5.27	2.98	5.50	8.26	8.02	19.37

Notes:

- The above Unaudited Standalone Financial Results of the Company for the quarter and six months ended 30th September, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13th November, 2025.
- The Company is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
- During the quarter ended 30 September 2025, the Company successfully completed the rights issue of 13,98,463 fully paid up Equity Shares of face value of ₹ 10 each for cash at a price of ₹ 357 per rights equity share (including a premium of ₹ 347 per rights equity share) aggregating up to ₹ 4992.51 lakhs, primarily for funding the capital expenditure for Greenfield Project at Pen. These equity shares were allotted on 25th August 2025.
- The figures for the corresponding previous periods have been reclassified/rearranged, wherever necessary, to make them comparable with the current periods.



For and on behalf of the Board of Directors

Mukund Mehta
Managing Director
DIN:- 00147876



Place : Mumbai

Dated: 13th November, 2025

KILITCH DRUGS (INDIA) LIMITED
STANDALONE BALANCE SHEET AS AT 30TH SEPTEMBER 2025
CIN:L24239MH1992PLC066718

(Rs. in Lakhs)

Particulars	As at 30th September, 2025	As at 31st March, 2025
	Unaudited	Audited
ASSETS		
Non-current assets		
- Property, Plant and Equipment	1,911.40	1,915.75
- Capital work-in-progress	9,787.86	4,729.45
- Other Intangible Assets	28.83	35.14
Financial assets		
- Investments	7,189.65	7,185.10
- Loans/Advances	5,664.45	5,423.15
- Other Financial Assets	-	1.81
Deferred tax assets (Net)	341.07	287.64
(A)	24,923.26	19,578.03
Current Assets		
- Inventories	1,301.03	1,530.96
Financial assets		
- Investments	5,390.37	4,951.77
- Trade Receivables	8,828.82	8,339.83
- Cash & Cash Equivalents	3,229.62	740.85
- Other Bank Balances	0.51	4.73
- Other Financial Assets	1.42	3.20
Other Current Assets	639.90	666.42
(B)	19,391.68	16,237.76
TOTAL ASSETS (A + B)	44,314.94	35,815.79
EQUITY AND LIABILITIES		
Equity		
- Equity Share Capital	1,748.08	1,608.23
- Other Equity	29,845.15	23,686.14
(A)	31,593.23	25,294.37
Liabilities		
Non-Current liabilities		
Financial Liabilities		
- Borrowings	5,134.14	2,777.04
Provisions	24.53	24.53
(B)	5,158.67	2,801.57
Current liabilities		
Financial Liabilities		
- Borrowings	3,194.21	2,132.43
- Trade Payables		
Micro and Small Enterprises	-	-
Others	3,485.88	4,742.22
- Other Financial Liabilities	6.52	7.03
Provisions	220.12	143.79
Current Tax Liabilities [Net]	626.46	668.55
Other Current Liabilities	29.87	25.84
(C)	7,563.06	7,719.85
TOTAL EQUITY AND LIABILITIES (A+B+C)	44,314.94	35,815.79



Place : Mumbai

Dated: 13th November, 2025

For and on behalf of the Board of Directors

(Signature)

Mukund Mehta
Managing Director

DIN:- 00147876



KILITCH DRUGS (INDIA) LIMITED
UNAUDITED STANDALONE CASH FLOW STATEMENT FOR SIX MONTHS ENDED 30TH SEPTEMBER, 2025
CIN:L24239MH1992PLC066718

(Rs. in Lakhs)

Particulars	For Six Months Ended 30th September, 2025		For Six Months Ended 30th September, 2024	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Net Profit / (Loss) before extraordinary items and tax		1,605.57		1,617.19
<u>Adjustments for:</u>				
Depreciation and amortization	102.57		75.16	
Interest income	(198.44)		(136.09)	
Dividend income	(1.32)		(0.38)	
(Profit)/Loss on sale of Investments	(367.73)		(546.31)	
Sundry Balances written back	6.10		-	
Provision for Gratuity & Leave Encashment	9.45		9.39	
Interest Expenses	126.52		91.04	
Provision for Expected Credit Loss	37.43		90.18	
Net unrealised exchange (gain) / loss	(289.40)	(574.82)	(128.23)	(545.24)
Operating profit / (loss) before working capital changes		1,030.75		1,071.95
<u>Changes in working capital:</u>				
<u>Operating Assets:</u>				
Inventories	229.93		(114.65)	
Trade receivables	(243.11)		(864.71)	
Other current assets	26.52		(62.82)	
Deposits & advances	(50.95)		(12.14)	
Other financial assets	1.78		1.97	
<u>Operating Liabilities:</u>				
Trade payables	(1,256.34)		487.18	
Other current liabilities	3.52		(5.92)	
Provisions	66.88	(1,221.77)	17.88	(553.21)
Gross cash flow from / (used in) operating activities		(191.02)		518.74
Direct Taxes (Paid) /refunded		(350.09)		(335.68)
Net cash flow from / (used in) operating activities (A)		(541.11)		183.06
B. CASH FLOW FROM INVESTING ACTIVITIES				
Purchases of Property, Plant & Equipment and CWIP	(5,150.32)		(1,925.58)	
Loans/Advances to related Parties	(190.35)		(89.47)	
Proceeds/(Purchases) (Net) of Current Investments	(7.23)		334.43	
Proceeds/(Purchases) (Net) of Non-Current Investments	(4.55)		(9.00)	
Movement in other Bank balances	6.03		(26.84)	
Interest received	198.44		136.09	
Dividend received	1.32		0.38	
		(5,146.66)		(1,579.99)
		(5,146.66)		(1,579.99)
Net cash flow from / (used in) investing activities (B)		(5,146.66)		(1,579.99)
C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds From Right Issue of Equity Share Capital (incl. Share Premium-net of share issue expenses)	4,884.21		-	
Proceeds from Borrowings (Net of Repayments)	3,418.87		76.58	
Interest paid	(126.52)		(91.04)	
Net cash flow from / (used in) financing activities (C)		8,176.56		(14.46)
Net increase / (decrease) in Cash and cash equivalents (A+B+C)		2,488.77		(1,411.39)
Cash and cash equivalents at the beginning		740.85		1,794.88
Cash and cash equivalents at the end		3,229.62		383.49
Cash and cash equivalents at the end *				
* Comprises:				
(a) Cash on hand		1.71		1.16
(b) Balances with banks				
(i) In current accounts		3,224.52		378.49
(ii) In earmarked accounts		3.39		3.84
		3,229.62		383.49



Place : Mumbai
Dated: 13th November, 2025

For and on behalf of the Board of Directors

(Signature)

Mukund Mehta
Managing Director
DIN:- 00147876



Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of Kilitch Drugs (India) Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,
The Board of Directors of
Kilitch Drugs (India) Limited

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of **Kilitch Drugs (India) Limited** ("the Parent"), and its' subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and half year ended 30th September, 2025 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This statement which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether Statement is free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, to the extent applicable.

4. The Statement includes the results of entities as given below:

List of Subsidiaries:

1. Monarchy Healthserve Private Limited
2. Kilitch Estro Biotech PLC – Foreign Subsidiary

5. (a) We did not review the interim financial results and other financial information in respect of one subsidiary whose interim financial results/information reflects, total assets of Rs. 1,814.94 Lakhs, total revenues of Rs. Nil and Rs. Nil, total net profit/(loss) after tax of Rs. (22.11) Lakhs and Rs. (43.95) Lakhs and total comprehensive income/(loss) of Rs. (22.11) Lakhs and Rs. (43.95) Lakhs for the quarter ended 30th September, 2025 and for the period from 1st April, 2025 to 30th September, 2025, respectively and net cash outflow of Rs. 0.01 Lakhs for the period from 1st April, 2025 to 30th September, 2025. These interim financial results and other financial information have been reviewed by other auditors, whose reports have been furnished to us by the management of the Company and our conclusion in so far as it relates to the affairs of such subsidiary is based solely on the report of other auditors.

(b) The Statement includes interim financial results and other financial information in respect of one foreign subsidiary which reflects, total assets of Rs. 5,703.22 Lakhs, total revenues of Rs. 1,112.39 Lakhs and Rs. 2,065.11 Lakhs, total net profit/(loss) after tax of Rs. (45.49) Lakhs and Rs. (276.83) Lakhs and total comprehensive income/(loss) of Rs. (45.49) Lakhs and Rs. (276.83) Lakhs for the quarter ended 30th September, 2025 and for the period from 1st April, 2025 to 30th September, 2025, respectively and net cash outflow of Rs. 159.76 Lakhs for the period from 1st April, 2025 to 30th September, 2025 as considered in the consolidated financial results. These financial statements have been furnished to us by the management and our opinion on the statement, in so far as it relates to the amounts included in respect of this subsidiary is solely based on such unaudited financial statements as certified by the management.


Our conclusion on the Statement is not modified in respect of the above matter.

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on management certified financial statements referred in paragraph 5 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For C Sharat & Associates
 Chartered Accountants
 FRN: 128593W

CHINTAN
 SHARATCHA
 NDRA SHAH

Digitally signed by
 CHINTAN
 SHARATCHANDRA
 SHAH
 Date: 2025.11.13
 15:38:45 +05'30'



Chintan Sharatchandra Shah
 Partner

Mem.No.: 127551
 UDIN: 25127551BMIIWH4640
 Date: 13/11/2025
 Place: Mumbai

KILITCH DRUGS (INDIA) LIMITED
CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30TH SEPTEMBER, 2025

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701
 Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com
 CIN:L24239MH1992PLC066718

(Rs. In Lakhs except Earnings per Share data)

Sr. No.	Particulars	CONSOLIDATED					
		Three Months Ended			Six Months Ended		Year Ended
		30-09-2025 Unaudited	30-06-2025 Unaudited	30-09-2024 Unaudited	30-09-2025 Unaudited	30-09-2024 Unaudited	31-03-2025 Audited
1	Income						
	Net Sales/Income from Operations	4,892.45	4,313.98	4,747.49	9,206.42	8,092.65	19,831.85
	Other Income	666.04	255.74	516.42	921.77	773.79	1,116.06
	Total Income	5,558.49	4,569.72	5,263.91	10,128.20	8,866.44	20,947.91
2	Expenses						
	Cost of Materials Consumed	2,429.28	2,549.00	2,442.56	4,978.28	4,306.67	10,574.97
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	206.90	(76.09)	16.54	130.81	5.55	(116.99)
	Employee Benefit Expenses	375.83	275.19	259.23	651.03	530.12	1,132.38
	Finance Cost	143.96	152.98	30.55	296.94	203.70	504.13
	Depreciation and Amortisation Expenses	86.28	84.32	60.50	170.60	145.61	311.02
	Export Product Registration/Commission	527.17	550.87	561.07	1,078.04	935.27	1,995.02
	Other expenses	849.16	688.55	858.82	1,537.71	1,539.87	3,099.96
	Total Expenses	4,618.58	4,224.82	4,229.27	8,843.43	7,666.79	17,500.49
3	Profit before Exceptional items (1-2)	939.91	344.90	1,034.64	1,284.77	1,199.65	3,447.42
4	Exceptional Items	-	-	-	-	-	-
5	Profit from ordinary activities before tax (3+4)	939.91	344.90	1,034.64	1,284.77	1,199.65	3,447.42
6	Less : Tax Expenses						
	Current Income Tax	178.14	129.86	216.09	308.00	342.59	985.00
	Deferred Tax	(42.23)	(11.21)	(42.63)	(53.44)	(15.31)	(31.59)
7	Profit after tax for the period from continuing operations (5-6)	804.00	226.25	861.18	1,030.21	872.37	2,494.01
8	Net Profit/(Loss) After Tax & Share in Profits /(Loss) of Associates	804.00	226.25	861.18	1,030.21	872.37	2,494.01
9	Other Comprehensive Income (after Tax)	(229.86)	293.49	(13.19)	63.64	102.83	(113.68)
10	Total Comprehensive Income (after taxes) (8+9)	574.14	519.74	847.99	1,093.85	975.20	2,380.33
11	Net Profit / (Loss) attributable to						
	a) Owner of the Company	818.97	302.59	861.70	1,121.56	995.72	2,670.06
	b) Non Controlling interest	(15.01)	(76.34)	(0.52)	(91.35)	(123.35)	(176.05)
12	Other Comprehensive Income attributable to						
	a) Owner of the Company	(229.86)	293.49	(13.19)	63.64	102.83	(113.68)
	b) Non Controlling interest	-	-	-	-	-	-
13	Total Income attributable to						
	a) Owner of the Company	589.11	596.08	848.51	1,185.20	1,098.55	2,556.38
	b) Non Controlling interest	(15.01)	(76.34)	(0.52)	(91.35)	(123.35)	(176.05)
14	Paid-Up equity share capital (Face Value Rs. 10 per share)	1,748.08	1,608.23	1,608.23	1,748.08	1,608.23	1,608.23
15	Other Equity						18,624.68
16	Earning per share (not annualised)						
	(a) Basic	4.97	1.88	5.36	6.85	6.19	16.60
	(b) Diluted	4.97	1.88	5.36	6.85	6.19	16.60

Notes:


- The above Unaudited Consolidated Financial Results of the Company for the quarter and six months ended 30th September, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 13th November, 2025.
- The Group is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
- During the quarter ended 30 September 2025, the Company successfully completed a rights issue of 13,98,463 fully paid up Equity Shares of face value of ₹ 10 each for cash at a price of ₹ 55 per rights equity share (including a premium of ₹ 347 per rights equity share) aggregating up to ₹ 4992.51 lakhs, primarily for funding the capital expenditure for Green field Project at Pen. These equity shares were allotted on 25th August 2025.
- The comparative figures for corresponding previous periods have been reclassified/rearranged, wherever necessary, to make them comparable with the current periods.



Place: Mumbai
 Date: 13th November, 2025

For and on behalf of the Board of Directors

Mukund P. Mehta
 Managing Director
 DIN : 00147876




KILITCH DRUGS (INDIA) LIMITED UNAUDITED CONSOLIDATED BALANCE SHEET AS AT 30TH SEPTEMBER, 2025 CIN:L24239MH1992PLC066718 (Rs. In Lakhs)		
Particulars	As at 30th September, 2025	As at 31st March, 2025
	Unaudited	Audited
ASSETS		
Non-current assets		
Property, plant and Equipment	4,522.18	4,552.43
Capital work-in-progress	9,787.86	4,729.45
Other Intangible assets	1,840.30	1,888.74
Financial assets		
- Investments	2,288.74	2,284.19
- Loans/Advances	151.97	142.19
- Other Financials Assets	-	1.81
Deferred tax assets (Net)	341.37	287.92
(A)	18,932.41	13,886.73
Current assets		
Inventories	1,301.03	1,530.96
Financial assets		
- Investments	5,390.37	4,951.77
- Trade and other receivables	9,291.00	8,473.88
- Cash and cash equivalents	3,309.05	980.05
- Other Bank Balances	0.51	4.73
- Other Financials Assets	1.42	3.20
Other current assets	1,639.74	1,447.06
(B)	20,933.12	17,391.65
TOTAL ASSETS (A + B)	39,865.53	31,278.38
EQUITY AND LIABILITIES		
Equity		
Equity Share capital	1,748.08	1,608.23
Other Equity	24,817.79	18,624.68
Equity attributable to the owners	26,565.87	20,232.91
Non-controlling interest	(148.67)	(187.11)
(A)	26,417.20	20,045.80
Liabilities		
Non-current liabilities		
Financial liabilities		
- Borrowings	5,134.14	2,777.04
Provisions	24.53	24.53
(B)	5,158.67	2,801.57
Current liabilities		
Financial liabilities		
- Borrowings	3,227.14	2,165.36
- Trade Payables		
Micro and Small Enterprises	-	-
Others	4,173.56	5,415.74
- Other financial liabilities	6.52	7.03
Provisions	226.13	148.48
Current tax Liabilities (Net)	626.43	668.55
Other current liabilities	29.88	25.85
(C)	8,289.66	8,431.01
TOTAL EQUITY AND LIABILITIES (A + B + C)	39,865.53	31,278.38

Place : Mumbai
Date : 13th November, 2025



For and on behalf of the Board of Directors

Mukund P. Mehta
Managing Director
DIN : 00147876



KILITCH DRUGS (INDIA) LIMITED UNAUDITED CONSOLIDATED CASH FLOW STATEMENT FOR THE SIX MONTHS ENDED ON 30TH SEPTEMBER, 2025 CIN:L24239MH1992PLC066718			
(Rs. In Lakhs)			
Particulars	For the Year ended 30th September, 2025		For the Year ended 30th September, 2024
A. CASH FLOW FROM OPERATING ACTIVITIES			
Net Profit / (Loss) before extraordinary items and tax		1,284.78	1,199.64
<u>Adjustments for:</u>			
Depreciation and amortisation	170.60		145.61
Interest income	(9.76)		(7.83)
Dividend income	(1.32)		(0.38)
(Profit)/Loss on sale of Investments	(367.73)		(546.31)
Sundry Balances written back	6.10		-
Provision for Gratuity & Leave Encashment	9.45		9.39
Interest Expenses	296.94		203.70
Provision for Expected Credit Loss	37.43		90.18
Net unrealised exchange (gain) / loss	(289.40)	(147.69)	(128.23)
Operating profit / (loss) before working capital changes		1,137.09	965.77
<u>Changes in working capital:</u>			
<u>Operating Assets:</u>			
Inventories	229.93		(114.65)
Trade receivables	(571.23)		(581.97)
Other current assets	(192.68)		(253.02)
Deposit & Advances	(9.79)		(12.10)
<u>Operating Liabilities:</u>			
Trade payables	(976.96)		554.83
Other financial liabilities	(0.51)		(0.62)
Other current liabilities	4.03		(5.26)
Short-term provisions	68.20	(1,449.02)	14.29
Gross cash flow from / (used in) operating activities		(311.93)	567.27
Direct Taxes (Paid) / refunded		(350.09)	(335.68)
Net cash flow from / (used in) operating activities		(662.02)	231.59
B. CASH FLOW FROM INVESTING ACTIVITIES			
Capital expenditure on PPE,CWIP including capital advances	(5,150.31)		(1,877.36)
Proceeds (Net) from the sale of Current investments	(7.18)		334.38
(Purchase)/Sale (Net) of long-term investments:	(4.55)		(9.01)
Movement in other Bank balance	6.03		(26.84)
Interest received	9.76		9.80
Dividend received	1.32		0.38
		(5,144.93)	(1,568.65)
Net cash flow from / (used in) investing activities (B)		(5,144.93)	(1,568.65)
C. CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds From Right Issue of Equity Share Capital (incl. Share Premium- net of share issue expenses)	4,884.21		-
Proceeds from Borrowings (Net of Repayments)	3,418.88		76.59
Proceeds from Minorities	129.80		100.66
Interest paid	(296.94)		(203.70)
		8,135.95	(26.45)
Net cash flow from / (used in) financing activities (C)		8,135.95	(26.45)
Net increase / (decrease) in Cash and cash equivalents (A+B+C)		2,329.00	(1,363.51)
Cash and cash equivalents at the beginning of the period		980.05	1,896.18
Cash and cash equivalents at the end of the period		3,309.05	532.67
Cash and cash equivalents at the end of the period *			
* Comprises:			
(a) Cash on hand		1.71	1.16
(b) Balances with banks			
(i) In current accounts		3,303.95	527.67
(ii) In earmarked accounts		3.39	3.84
		3,309.05	532.67



Place : Mumbai
Date : 13th November, 2025

For and on behalf of the Board of Directors

Mukund P. Mehta
Managing Director
DIN: 00147876

